NanOlogy, LLC CEO David J. Arthur Discusses Their PURCISION™ Technology Advancing Intratumoral Therapy to Treat Cancer

On February 26, 2026 CEOCFO Magazine, an independent business and investor publication that highlights important technologies and companies, reported an interview with David J. Arthur, CEO, of Fort Worth, Texas based NanOlogy, LLC advancing their PURCISION technology platform aimed at improving the treatment of cancer without increasing toxicity.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

David J. Arthur, during the interview with CEOCFO’s Senior Editor Lynn Fosse, addressing the concept behind NanOlogy said, "NanOlogy is a clinical-stage oncology company advancing a technology platform aimed at improving the treatment of cancer without increasing toxicity. The technology, called PURCISION, forms particles of pure cancer drugs optimized for intratumoral (IT) delivery. These particles are delivered directly to the site of the tumor, where they continuously deliver high local concentration of drug to the tumor over time, with minimal systemic toxicity. NanOlogy has established feasibility of the PURCISION technology in many small molecules and has studied three intratumorally delivered investigational drugs preclinically or clinically in several solid tumors. The technology, supporting data, and team all attracted me to take on the role of CEO as I believe my background and experience can help position the company to benefit cancer patients and create long term value to shareholders. I think NanOlogy has got to be one of the more attractive companies out there right now."

On the need to improve the treatment of solid tumors, David J. Arthur told Lynn, "A significant unmet need in oncology is to improve the treatment of solid tumors. Solid tumors are very hard to treat and rational combinations including chemotherapies, and newer agents like targeted therapies and immunotherapies, will remain standard of care (SOC) for the foreseeable future. Research has shown that chemo and targeted therapies help kill the tumor and elicit an immune response, called "immune priming", to help improve solid tumor response to immunotherapy.

Over the years, researchers have been working on many methods to target the delivery of cancer drugs to help improve solid tumor response. Targeted therapies given systemically are an example but have not lived up to their promise because of off-target toxicities and other limitations."

As for how their technology approach is different, David J. Arthur shared, "Instead of systemic administration, the PURCISION technology is designed to be given locally to directly kill the primary tumor or tumors and prime the immune system to increase solid tumor response to newer SOC therapies. Our proprietary technology uniquely uses supercritical fluid carbon dioxide as an antisolvent to form what we have come to characterize as large surface area microparticles, or "LSAMs", of pure drug optimized for intratumoral delivery. The microparticles retain a particle size that is sufficient for tumor retention but with a huge increase in surface area that allows for high local drug release over time. LSAMs are covered by a composition of matter patent forming the foundation of more than 100 issued patents filed globally protecting composition, use, formulation, and technology."

Asked where they are in the development process, David J. Arthur replied, "There are many different types of solid tumors, and most are now accessible because of advancements in imaging and advancements in interventional procedures over the last decade. One of the things that excited me about NanOlogy when I came onboard was the breadth of clinical experience that they have already achieved with their LSAM investigational drugs. On two LSAM assets, NanOlogy has run seven clinical trials across six different solid tumors including bladder, lung, pancreas, prostate, ovarian, and peritoneal cancers. We are now talking with Strategic Pharma and other groups to advance those assets further in clinical development in prioritized indications."

Pointing to another asset they have in development, David J. Arthur offered, "Another asset we are excited about is the development of cisplatin into LSAM-Cisplatin. Cisplatin is a chemotherapy that has been around for a while with many uses but has terrible side effects when given systemically. We have developed a clinical formulation of LSAM-Cisplatin and are nearing completion of preclinical studies with our lead indication for a rare devastating pediatric brainstem tumor called diffuse intrinsic pontine glioma (DIPG). This is a devastating, highly lethal cancer in children, with typical onset between the ages of two and ten. There is no treatment other than radiation. Unfortunately, the median survival for these children after diagnosis is only 10 months."

As for their approach to DIPG, David J. Arthur continued, "A key problem is that DIPG is deep in the brain. It is very difficult to get systemically administered drugs through the blood brain barrier to the tumor, and these tumors are inoperable because of their location. But recent advances have allowed us to use a highly precise MRI guided targeting system, to inject LSAM-Cisplatin directly into the tumor. We are hopeful that delivery LSAM-Cisplatin directly to the tumor will offer hope for children and families facing this horrible disease and that LSAM-Cisplatin could become one of the first approved medicines with significant benefit for the treatment of DIPG."

Addressing emerging interest in Intratumoral Therapy, David J. Arthur told CEOCFO, "Intratumoral therapy is rapidly gaining momentum as a potential important part of the treatment of solid tumors – in early disease to prevent or delay progression and in late disease, combined with newer systemic agents, to improve response without the severe stacked toxicities associated with systemic combinations. We are beginning to see the proverbial hockey stick in interest emerge – whereas only a few clinical trials involving IT modalities were underway a few years ago, almost 200 clinical trials are currently underway. Large pharma is beginning to take note, too, with companies like J&J already significantly investing in the space. NanOlogy is a leader in IT therapy aimed at improving solid tumor response without increasing toxicity with growing evidence in support of this aim."

(Press release, NanOlogy, FEB 26, 2026, View Source;utm_medium=rss&utm_campaign=nanology-llc-ceo-david-j-arthur-discusses-their-purcision-technology-advancing-intratumoral-therapy-to-treat-cancer [SID1234663127])

MacroGenics to Participate in Upcoming Investor Conferences

On February 26, 2026 MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, reported that the Company’s management team will participate in the following investor conferences in March:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TD Cowen 46th Annual Health Care Conference (Boston, MA). MacroGenics’ President and CEO, Eric Risser, will participate in a hybrid presentation and fireside chat on Tuesday, March 3, at 3:10 pm ET. MacroGenics’ management will also participate in one-on-one meetings.
Leerink Partners 2026 Global Healthcare Conference (Miami, FL). Mr. Risser will participate in a fireside chat on Tuesday, March 10, at 1:40 pm ET. MacroGenics’ management will also participate in one-on-one meetings.
The Citizens 2026 Life Sciences Conference (Miami, FL). Mr. Risser will participate in a fireside chat on Wednesday, March 11, at 10:45 am ET. MacroGenics’ management will also participate in one-on-one meetings.
Barclays 28th Annual Global Healthcare Conference (Miami, FL). Mr. Risser will participate in a fireside chat on Thursday, March 12, at 10:00 am ET. MacroGenics’ management will also participate in one-on-one meetings.

Webcasts of these presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics’ website at View Source The Company will maintain an archived replay of the webcasts on its website for 30 days.

(Press release, MacroGenics, FEB 26, 2026, View Source [SID1234663123])

New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors

On February 26, 2026 PMV Pharmaceuticals, Inc. ("PMV Pharma" or the "Company"; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, reported that results from the Phase 1, first-in-human portion of the ongoing Phase 1/2 PYNNACLE study evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation were published in the New England Journal of Medicine (NEJM). The publication provides a summary of the Phase 1 safety and efficacy results across 77 patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study published in NEJM entitled, "Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors," highlighted the antitumor activity of rezatapopt in heavily pretreated patients across multiple solid tumor-types establishing proof-of-concept for p53 reactivation. All responding patients had a TP53 Y220C mutation and were KRAS wild-type. The manuscript can be accessed here.

In the Phase 1 portion of the PYNNACLE clinical trial, 77 heavily pretreated patients with advanced solid tumors harboring a TP53 Y220C mutation received oral rezatapopt across dose-escalation cohorts to determine the maximum tolerated dose and recommended Phase 2 dose (RP2D), characterize safety, pharmacokinetics, and biomarker effects. Rezatapopt was generally well tolerated; dose-limiting toxicities were infrequent, supporting selection of the RP2D. Objective responses were observed across multiple tumor types. Clinical activity and biomarker data were consistent with selective binding to the Y220C pocket and restoration of wild-type p53 tumor suppressor function.

"Publication of the rezatapopt Phase 1 results in the New England Journal of Medicine underscores the emerging clinical impact of reactivating p53 in patients whose cancers are driven by a TP53 Y220C mutation," said Deepika Jalota, Pharm.D., Chief Development Officer of PMV Pharma. "These peer-reviewed findings further validate our scientific approach, support our registrational Phase 2 strategy and our plan to submit a New Drug Application in platinum-resistant/refractory ovarian cancer in the first quarter of 2027. We remain focused on advancing rezatapopt as a potential first-in-class therapy for ovarian cancer patients harboring a TP53 Y220C mutation, an area of high unmet medical need."

In October 2025, the Company presented updated interim clinical results from the Phase 2 pivotal portion of the PYNNACLE study, highlighting confirmed responses in patients whose tumors were TP53 Y220C mutated and KRAS wild-type across eight tumor types, including ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder cancers, and ampullary carcinoma. As of the September 4, 2025 data cutoff date, the overall response rate (ORR) across all cohorts was 34% (35/103 patients), with an ORR of 46% (22/48 patients) in ovarian cancer per investigator assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, including confirmed and unconfirmed responses. Across all cohorts, the median time to response was 1.3 months, and the median duration of response was 7.6 months. In the ovarian cancer cohort, the median time to response was 1.3 months and the median duration of response was 8.0 months.

About Rezatapopt
Rezatapopt (PC14586) is a first-in-class, small molecule, p53 reactivator designed to selectively bind to the pocket in the p53 Y220C mutant protein, restoring the wild-type tumor-suppressor function. The U.S. Food and Drug Administration granted Fast Track designation to rezatapopt for the treatment of patients with locally advanced or metastatic solid tumors with a p53 Y220C mutation.

About the PYNNACLE Clinical Trial
The ongoing Phase 1/2 PYNNACLE clinical trial is evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation. The primary objective of the Phase 1 portion of the clinical trial was to determine the maximum tolerated dose and recommended Phase 2 dose (RP2D) of rezatapopt when administered orally to patients. Safety, tolerability, pharmacokinetics and effects on biomarkers were also assessed. The Phase 2 portion is a registrational, single arm, expansion basket clinical trial comprising five cohorts (ovarian, lung, breast, and endometrial cancers, and other solid tumors) with the primary objective of evaluating the efficacy of rezatapopt at the RP2D in patients with TP53 Y220C and KRAS wild-type advanced solid tumors. For more information about the Phase 1/2 PYNNACLE clinical trial, refer to www.clinicaltrials.gov (NCT trial identifier NCT04585750).

(Press release, PMV Pharma, FEB 26, 2026, View Source [SID1234663108])

TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03

On February 26, 2026 TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, reported completion of enrollment into Cohort C of the ALLOHA study. Patients in Cohort C are being treated using the new commercial-ready manufacturing process. The Company also announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) applications for TSC-102-A01 and TSC-102-A03 for patients with HLA types A*01:01 and A*03:01, respectively.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited about the potential of TSC-101 to treat residual disease and prevent relapse in patients undergoing hematopoietic cell transplantation," said Gavin MacBeath, Ph.D., Chief Executive Officer. "We have now enrolled over ten patients in Cohort C of the ALLOHA study where we are treating patients with our new commercial-ready manufacturing process. We look forward to sharing data from this cohort in the second quarter of this year, prior to launching our Phase 3 study. We are also pleased to announce that the FDA has cleared our IND applications for TSC-102-A01 and TSC-102-A03, and we look forward to initiating a Phase 1 trial with these candidates in the second half of this year. We believe the addition of these product candidates will nearly double the addressable U.S. patient population in our heme program."

"During the Tandem Meetings of ASTCT and CIBMTR, we highlighted the relationship between donor chimerism and long-term outcomes in patients following HCT," added Chrystal U. Louis, M.D., Chief Medical Officer. "Specifically, patients that achieved complete donor chimerism by month two after transplant using a high-sensitivity assay have a significantly lower probability of relapse (HR=4.6, p=0.02) compared to those who did not achieve complete donor chimerism. We look forward to sharing early chimerism data from Cohort C and formally initiating our pivotal study for TSC-101."

The Phase 1 ALLOHA study is evaluating TSC-101 in A*02:01-positive patients with heme malignancies undergoing allogeneic hematopoietic cell transplantation (allo-HCT). TScan plans to share safety and early chimerism data from Cohort C in the second quarter of 2026. The Company also plans to launch a pivotal trial for TSC-101 in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in the second quarter of 2026.

The U.S. FDA clearance of INDs for TSC-102-A01 and TSC-102-A03 continues the momentum in TScan’s heme program by expanding HLA coverage to include patients who are HLA-A*01:01-positive or HLA-A*03:01-positive, respectively. These TCR-T therapy candidates target CD45, a protein broadly expressed in heme cells but absent in non-heme tissues.

TScan plans to initiate a Phase 1 trial for both TSC-102-A01 and TSC-102-A03 in the second half of 2026. Products will be manufactured using the commercial-ready process and will enroll patients with various hematologic malignancies undergoing allo-HCT using either reduced intensity conditioning or myeloablative conditioning. The multi-center Phase 1 trial is designed to assess safety and initial efficacy of these TCR-T therapy candidates.

(Press release, TScan Therapeutics, FEB 26, 2026, View Source [SID1234663107])

Starton Therapeutics Files Patent Application for the Use of Multi-Specific Antibody-Based Therapies in Combination with its Proprietary, Continuous Low-Dose Immunomodulatory Therapy, STAR-LLD, a formulation of Lenalidomide, for the Treatment of Blood Cancer

On February 26, 2026 Starton Therapeutics Inc. ("Starton"), a clinical-stage biotechnology company employing standard-of-care therapies with proprietary continuous delivery technologies, reported that it has filed a patent application for the use of multi-specific (i.e., bi- and tri-specific) antibody-based therapies in combination with the Company’s proprietary, continuous low-dose IMiD, which is a subcutaneous administration of lenalidomide, STAR-LLD, for the treatment of cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to announce the filing of this provisional patent application," stated Pedro Lichtinger, Chairman and Chief Executive Officer of Starton. "Although lenalidomide and other IMiDs are being studied in combination with multi-specific antibodies, side effect profiles are thought to limit widespread acceptance by oncologists. We believe our continuous subcutaneous delivery of a low-dose formulation of lenalidomide has the potential to improve the side effect profile while sustaining T-cell persistence and response durability."

About STAR-LLD

STAR-LLD is a continuous delivery lenalidomide (LLD) in development seeking to expand and replace the standard-of-care for the most common blood cancers, multiple myeloma (MM), and chronic lymphocytic leukemia (CLL). A preclinical proof-of-concept study for subcutaneous STAR-LLD demonstrated that MM tumors caused by human myeloma cells grew 25-fold if untreated, five-fold when treated with daily lenalidomide, and shrank by 80% with STAR-LLD over a single 28-day cycle. The study also showed a 100% overall response rate (ORR) using continuous delivery LLD with 20% of animals in this cohort tumor-free after 100 days; by contrast, there was a 0% ORR in animals treated with a 70% higher dose of lenalidomide given in single daily doses. In addition, a Phase 1b clinical study of six relapsed/refractory MM patients resulted in all patients that received STAR-LLD achieving an objective response (1 CR and 5 PRs); no patients experienced drug-related anemia, neutropenia, leukopenia, or thrombocytopenia greater than grade 2 in up to 12 cycles of therapy. The Phase 1b clinical study concluded that continuous delivery of low dose lenalidomide (STAR-LLD) provides meaningful efficacy and improved tolerability with no grade > 2 drug-related hematologic toxicity.

(Press release, Starton Therapeutics, FEB 26, 2026, View Source [SID1234663106])